Corporate Services

We provide our corporate customers award proven services and products in genetic testing and analysis, under medical supervision. Explore our services below.

HEALTHPLAN

Genetic susceptibility for development of cardiovascular diseases, cancers and other diseases as well as response to certain medications and new insights into genetically determined physical characteristics and abilities

Genetic risk for certain diseases

  • Alzheimer’s
  • Asthma
  • Atrial fibrillation
  • Coeliac disease
  • Glaucoma
  • Multiple sclerosis
  • High blood pressure
  • Psoriasis
  • Rheumatoid arthritis
  • Restless leg syndrome
  • Diabetes mellitus type 1
  • Diabetes mellitus type 2
  • Myocardial infarction (heart attack)
  • Venous thromboembolism
  • Gallstones

Genetic risk factors for developing cancer

  • Skin cancer (basal-cell carcinoma)
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer

Medicament response

  • Prevention of blood clotting
  • Regulation of blood sugar
  • Inhibition of gastric acid secretion
  • Treatment of stable coronary artery disease
  • Lowering blood cholesterol
  • Prevention of blood clotting

Genetically determined physical features and traits

  • Eye colour
  • Sensitivity to pain
  • Muscle structure
  • Nicotine addiction
  • Resistance to infection with noroviruses
  • Resistance to malaria (type duffy)
  • Baldness
  • Alcohol metabolism
  • Caffeine metabolism
  • Lactose metabolism
  • Episodic memory
  • Type of earwax
  • Learning from mistakes
  • Perception of bitter taste
£408.00
MORE INFO

CANCER SCREENING

A simple and accurate genetic test based on the newest technologies of next generation sequencing. It screens for mutations in genes associated with 17 different cancers including hereditary breast and ovarian cancer (BRCA1 and BRCA2).

Who is it for?

  • Patients with family history of cancer and concerned about thier own genetic risk.
  • Men and women diagnosed with breast cancer, in particular women under 50 years of age whom have had multiple breast or ovarian cancers.
  • Significantly improves detecting patients, identified as carriers of mutations by using targeted state of the art surveillance strategies.
  • Avoid unnecessary medical interventions for patients who may have not tested positive for any known mutations in their families.

What are the clinical benefits

  • Improving outcomes: Potentially improves outcomes for patients identified as carriers of mutations with targeted surveillance or early intervention.
  • Avoiding unnecessary interventions: Avoids unnecessary interventions for patients who do not test positive for the mutation known in their family.
  • Counselling patients: Counsel patients on the underlying genetic causes of hereditary cancer in their family.

17 Hereditary cancers

  • Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Renal Cancer
  • Multiple Endocrine Neoplasia
  • Thyroid Cancer
  • Parathyroid Carcinoma
  • Neurofibromatosis
  • Pheochromocytoma
  • Familial Paraganglioma
  • Retinoblastoma
  • Melanoma
  • Chondrosarcoma
  • Pancreatic Cancer
MORE INFO
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram